← Back to All US Stocks

Cigna Group (CI) Stock Fundamental Analysis & AI Rating 2026

CI NYSE Hospital & Medical Service Plans DE CIK: 0001739940
Updated This Month • Analysis: Mar 19, 2026 • SEC Data: 2025-12-31
Combined AI Rating
BUY
76% Confidence
AGREEMENT
BUY
78% Conf
HOLD
73% Conf

📊 CI Key Takeaways

Revenue: $274.9B
Net Margin: 2.2%
Free Cash Flow: $8.6B
Current Ratio: 0.85x
Debt/Equity: 0.74x
EPS: $22.18
AI Rating: BUY with 78% confidence
Cigna Group (CI) receives a BUY rating with 76% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $274.9B, net profit margin of 2.2%, and return on equity (ROE) of 14.3%, Cigna Group demonstrates strong fundamentals in the Healthcare sector. Below is our complete CI stock analysis for 2026.

Is Cigna Group (CI) a Good Investment?

Claude

Cigna demonstrates solid fundamental health with strong revenue growth of 11.2% YoY, robust free cash flow generation of $8.6B, and healthy interest coverage of 6.6x. However, profitability margins are compressed at 2.2% net margin and liquidity is concerning with a current ratio below 1.0x, limiting upside potential.

ChatGPT

Cigna Group shows solid scale, double-digit revenue growth, and strong cash generation, with leverage and interest coverage that remain manageable for a large healthcare services business. However, profit quality looks mixed because net income declined despite strong revenue growth and EPS expansion, while margins remain thin and liquidity ratios below 1.0x leave less short-term balance sheet flexibility.

Why Buy Cigna Group Stock? CI Key Strengths

Claude
  • + Strong revenue growth of 11.2% YoY indicates expanding market presence and demand
  • + Robust free cash flow of $8.6B ($8.6B FCF with $9.6B operating cash flow) supports dividends and deleveraging
  • + Solid interest coverage ratio of 6.6x demonstrates comfortable debt servicing capacity
  • + Reasonable debt-to-equity ratio of 0.74x indicates balanced capital structure
  • + Meaningful ROE of 14.3% shows efficient equity utilization
ChatGPT
  • + Revenue growth of 11.2% indicates the business is still expanding at meaningful scale
  • + Operating cash flow of $9.60B and free cash flow of $8.55B support debt service, reinvestment, and capital returns
  • + Debt/equity of 0.74x and interest coverage of 6.6x suggest leverage is material but currently manageable

CI Stock Risks: Cigna Group Investment Risks

Claude
  • ! Weak liquidity position with current ratio of 0.85x and quick ratio of 0.72x raises near-term operational concerns
  • ! Thin net profit margin of 2.2% leaves minimal room for operational disruptions or cost pressures
  • ! Net income declined 5.3% YoY despite 11.2% revenue growth, suggesting margin compression and cost control challenges
  • ! Substantial long-term debt of $30.9B relative to equity of $41.7B limits financial flexibility
  • ! Operating margin of only 3.3% is modest for the sector and vulnerable to healthcare cost inflation
ChatGPT
  • ! Net income declined 5.3% YoY, indicating earnings pressure despite higher revenue
  • ! Operating margin of 3.3% and net margin of 2.2% leave limited room for execution mistakes or cost pressure
  • ! Current ratio of 0.85x and quick ratio of 0.72x indicate weaker near-term liquidity positioning

Key Metrics to Watch

Claude
  • * Net margin trend and operating leverage as revenue scales
  • * Operating cash flow stability and free cash flow generation sustainability
  • * Current ratio improvement through asset management or liability reduction
  • * Long-term debt trajectory and deleveraging progress
  • * Medical loss ratios and claim cost management in core health plans
ChatGPT
  • * Net income growth relative to revenue growth
  • * Operating margin and free cash flow margin

Cigna Group (CI) Financial Metrics & Key Ratios

Revenue
$274.9B
Net Income
$6.0B
EPS (Diluted)
$22.18
Free Cash Flow
$8.6B
Total Assets
$157.9B
Cash Position
$7.7B

💡 AI Analyst Insight

The relatively thin 3.1% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.

CI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin 3.3%
Net Margin 2.2%
ROE 14.3%
ROA 3.8%
FCF Margin 3.1%

CI vs Healthcare Sector: How Cigna Group Compares

How Cigna Group compares to Healthcare sector averages

Net Margin
CI 2.2%
vs
Sector Avg 12.0%
CI Sector
ROE
CI 14.3%
vs
Sector Avg 15.0%
CI Sector
Current Ratio
CI 0.8x
vs
Sector Avg 2.0x
CI Sector
Debt/Equity
CI 0.7x
vs
Sector Avg 0.6x
CI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Cigna Group Stock Overvalued? CI Valuation Analysis 2026

Based on fundamental analysis, Cigna Group has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
14.3%
Sector avg: 15%
Net Profit Margin
2.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.74x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Cigna Group Balance Sheet: CI Debt, Cash & Liquidity

Current Ratio
0.85x
Quick Ratio
0.72x
Debt/Equity
0.74x
Debt/Assets
73.5%
Interest Coverage
6.57x
Long-term Debt
$30.9B

CI Revenue & Earnings Growth: 5-Year Financial Trend

CI 5-year financial data: Year 2021: Revenue $174.1B, Net Income N/A, EPS $13.44. Year 2022: Revenue $180.5B, Net Income N/A, EPS $22.96. Year 2023: Revenue $195.3B, Net Income N/A, EPS $15.75. Year 2024: Revenue $247.1B, Net Income N/A, EPS $21.41. Year 2025: Revenue $274.9B, Net Income $5.2B, EPS $17.39.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Cigna Group's revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $17.39 reflects profitable operations.

CI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.1%
Free cash flow / Revenue

CI Quarterly Earnings & Performance

Quarterly financial performance data for Cigna Group including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $63.7B $825.0M $2.63
Q2 2025 $60.5B $1.4B $4.43
Q1 2025 $57.3B -$212.0M $-0.97
Q3 2024 $49.0B $825.0M $2.63
Q2 2024 $48.6B $1.4B $4.43
Q1 2024 $46.5B -$212.0M $-0.97
Q3 2023 $45.3B $1.4B $4.74
Q2 2023 $45.5B $1.5B $4.89

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Cigna Group Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$9.6B
Cash generated from operations
Stock Buybacks
$3.6B
Shares repurchased (TTM)
Capital Expenditures
$1.1B
Investment in assets
Dividends Paid
$1.6B
Returned to shareholders

CI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Cigna Group (CIK: 0001739940)

📋 Recent SEC Filings

Date Form Document Action
Mar 13, 2026 DEF 14A ci-20260312.htm View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772583603.xml View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772583564.xml View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772583534.xml View →
Mar 3, 2026 4 xslF345X05/wk-form4_1772583480.xml View →

Frequently Asked Questions about CI

What is the AI rating for CI?

Cigna Group (CI) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are CI's key strengths?

Claude: Strong revenue growth of 11.2% YoY indicates expanding market presence and demand. Robust free cash flow of $8.6B ($8.6B FCF with $9.6B operating cash flow) supports dividends and deleveraging. ChatGPT: Revenue growth of 11.2% indicates the business is still expanding at meaningful scale. Operating cash flow of $9.60B and free cash flow of $8.55B support debt service, reinvestment, and capital returns.

What are the risks of investing in CI?

Claude: Weak liquidity position with current ratio of 0.85x and quick ratio of 0.72x raises near-term operational concerns. Thin net profit margin of 2.2% leaves minimal room for operational disruptions or cost pressures. ChatGPT: Net income declined 5.3% YoY, indicating earnings pressure despite higher revenue. Operating margin of 3.3% and net margin of 2.2% leave limited room for execution mistakes or cost pressure.

What is CI's revenue and growth?

Cigna Group reported revenue of $274.9B.

Does CI pay dividends?

Cigna Group pays dividends, with $1,611.0M distributed to shareholders in the trailing twelve months.

Where can I find CI SEC filings?

Official SEC filings for Cigna Group (CIK: 0001739940) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CI's EPS?

Cigna Group has a diluted EPS of $22.18.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is CI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Cigna Group has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is CI stock overvalued or undervalued?

Valuation metrics for CI: ROE of 14.3% (sector avg: 15%), net margin of 2.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy CI stock in 2026?

Our dual AI analysis gives Cigna Group a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is CI's free cash flow?

Cigna Group's operating cash flow is $9.6B, with capital expenditures of $1.1B. FCF margin is 3.1%.

How does CI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 2.2% (avg: 12%), ROE 14.3% (avg: 15%), current ratio 0.85 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Browse: Buy Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI